Skip to main content

Table 2 Reasons against participation in medicinal studies

From: Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate

Reasons for non-participation

Statistical output

Inconspicuous mammography result

Inconspicuous result of a mammography (42%, n = 84) [15]

Additional chronic and/or acute sickness

Current chronic or acute sickness (20%, n = 40) [15], having a higher risk of developing other diseases than breast cancer (more than 50%, n > 14) [19]

Skepticism towards clinical studies

General skepticism towards clinical studies (2%, n = 4) [15]

Feeling of becoming an "experiment" by participating

The thought of being an experiment (10%, n = 3) [11]

Additional family problems or no family support

Family problems (5%, n = 9) [18]

Fear of possible side effects

Side effects (14%, n = 4) [11], (3%, n = 6) [15], 31% (n = 59) [18], 35% (n = 8) [19], willingness decreased from 72% (n = 324) to 52% after explanation of side effects, and to 45% after uterine cancer was mentioned [17]

Preference of a certain treatment form

Preferences regarding chemotherapy (21%, n = 6) [11], not the same advantages as a menopausal hormone replacement therapy (22%, n = 5) [19]

Additional time necessary

Level of trial inconvenience regarding to the time requirements (P = 0.002, OR = 0.10, 95%CI [0.02-0.44]) [12], need too much time for the study (7%, n = 14) [15], additional time and effort needed (22%, n = 5) [19]

Study lasts too long

Aversion to taking tamoxifen for 5 years (14%, n = 4) [11], study duration (6%, n = 11) [18]

Too far to travel from home to place of study

Too far to travel from home to the examination center (12%, n = 24) [15], distance (4%, n = 8) [18]

Randomization

Aversion regarding the allotment of treatments in the study (38%, n = 11) or regarding the randomization (17%, n = 5) [11], randomization (39%, n = 9) [19]

Fear of medication abuse

Medication abuse (33%, n = 64) [18]

Incompatibility of own therapy and study medication

Incompatibility of their hormone replacement therapy with the study medication (22%, n = 5) [19]

Concern of not receiving appropriate therapy for oneself

Concern of receiving the appropriate treatment (7%, n = 2) [11]

Not willing to lose control over personal decisions

Loss of control (7%, n = 2) [11], women who refused showed preferences regarding personal decision making (72%) versus women who accepted (35%) (P < 0.001) [16]

Not willing to decide for oneself regarding participation

Not want to make own decision because physician should decide (10%, n = 3) [11]

Physician's advice not to participate

Physician counsel not to participate (24%, n = 46) [18]